Rishi Gupta
Private Equity Partner @ OrbiMed
Rishi Gupta is a Series A investor at OrbiMed focused on Biotechnology and Health Care. Rishi Gupta, J.D., is a Private Equity Partner. Previously, he was a healthcare investment banker at Raymond James & Associates, served as Manager of Corporate Development at Veritas Medicine, and was a summer associate at Wachtell, Lipton, Rosen & Katz. Mr. Gupta has published scientific articles on the mechanisms of HIV entry intohost cells and legal articles on intellectual property laws in the developing world. He received his A.B. degree magna cum laude in Biochemical Sciences from Harvard College and holds a J.D. from the Yale Law School.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 42%
Last updated:
For AI agents: llms.txt
Industries Rishi Gupta invests in
Stages Rishi Gupta invests in
Countries Rishi Gupta invests in
Investment Focus
Industry
- Biotechnology 7 (58%)
- Health Care 4 (33%)
- Therapeutics 4 (33%)
- Medical 2 (17%)
- Retail 1 (8%)
Stage
- Series A 7 (58%)
- Series B 3 (25%)
- Seed 1 (8%)
- Angel 1 (8%)
Country
- United States 7 (58%)
- India 1 (8%)
- United Kingdom 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CHARM Therapeutics
|
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins. | $80M / Series B / Sep 02, 2025 | |
Helicore Biopharma
|
Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders. | $65M / Series A / Jan 28, 2025 | |
Aer Therapeutics
|
Aer Therapeutics is a clinical-stage biopharmaceutical company that develops an approach to treat lung disease with excess mucus and mucus plugs. The company focuses on treating respiratory diseases with significant unmet needs, such as COPD, cystic fibrosis, and asthma. | $36M / Series A / Apr 13, 2023 | |
Delfi Diagnostics
|
Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. | $225M / Series B / Jul 18, 2022 | |
|
CHARM Therapeutics
|
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins. | $50M / Series A / Jun 09, 2022 | |
|
Delfi Diagnostics
|
Delfi Diagnostics detect cancer early, when it is most curable, using high precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. | $101.1M / Series A / Jan 12, 2021 | |
Enliven Therapeutics
|
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectivelydevelop precision oncology therapeutics that enhance overall patient well-being.Founded in July 2019 by Sam Kintz, MBA, Joe Lyssikatos, PhD, and Anish Patel, PharmD, Enliven Therapeutics is based in Boulder, Colorado. | $55M / Series A / Dec 07, 2020 | |
Modis Therapeutics
|
Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases. | $30M / Series A / Oct 01, 2018 | |
Turnstone Biologics
|
Turnstone Biologics is a privately-held clinical-stage biotech company. Turnstone Biologics’ mission is to deliver breakthrough cancer immunotherapies by advancing two leading and complementary platforms targeting tumor immunity, to improve survival for people with cancer. | $41.4M / Series B / Nov 02, 2016 | |
Attenua
|
Attenua, Inc. is a virtual biotech company formed to develop therapies for debilitating conditions neglected by Big Pharma's shift to specialty Pharma and biologics. They believe small molecule Blockbuster drugs that would benefit millions are still to be discovered.They have assembled a team of leading scientists and ex-Big Pharma advisorswith many years of drug development expertise. Their team has previous work experience at Merck, GSK, AstraZeneca, and Genentech. | $35M / Series A | |
| See all 12 investments → | |||
Co-Investors
F-Prime
7 deals together
Khosla Ventures
4 deals together
OUP (Osage University Partners)
3 deals together
5AM Ventures
2 deals together
AV8 Ventures
2 deals together
Cowen Healthcare Investments
2 deals together
About OrbiMed
OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investmentsseries of venture capital funds and a family of public equity investment funds.
OrbiMed Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dina Chaya
Partner
|
|||
Kevin Koch
Venture Partner
|
|||
|
Rishi Gupta
Private Equity Partner
|
|||
Sunny Sharma
Senior Managing Director
|
|||
Tadd S. Wessel
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Rishi Gupta invest in?
Rishi Gupta invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Rishi Gupta last invest?
The most recent investment recorded for Rishi Gupta closed in Sep 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
